<DOC>
	<DOCNO>NCT01431794</DOCNO>
	<brief_summary>This open-label phase 1/2 study combine chemotherapy agent gemcitabine nab-paclitaxel oral hedgehog inhibitor LDE225 . The objective ass tolerability resection rate patient borderline resectable pancreatic adenocarcinoma use treatment .</brief_summary>
	<brief_title>Gemcitabine + Nab-paclitaxel With LDE-225 ( Hedgehog Inhibitor ) Neoadjuvant Therapy Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>The investigator propose treat 6-12 patient phase 1 portion 40 patient phase 2 stage . Phase 1 Stage : 1 . Four cycle gemcitabine 1000 mg/m2 nab-paclitaxel 125 mg/m2 day 1 , 8 15 combination escalate dos LDE-225 . After completion neoadjuvant therapy , subject receive combine chemotherapy radiation . Then subject eligible resection go ahead surgery . Following resection , subject complete two additional cycle gemcitabine 1000 mg/m2 nab-paclitaxel 125 mg/m2 combination LDE-225 . Phase 2 Stage : In Phase 2 stage patient randomize receive gemcitabine nab-paclitaxel without hedgehog inhibitor LDE225 : 1 . Arm A : Four cycle gemcitabine 1000 mg/m2 nab-paclitaxel 125 mg/m day 1 , 8 15 combination LDE-225 recommend phase 2 dose . 2 . Arm B : Four cycle gemcitabine 1000 mg/m2 nab-paclitaxel 125 mg/m day 1 , 8 15 . After completion neoadjuvant therapy , subject receive combine chemotherapy radiation . Then subject eligible resection go ahead surgery . Following resection , subject complete two additional cycle pre-surgical therapy . Several correlative laboratory study conduct course study . They design around goal provide u good understand stroma-tumor interaction intra-tumoral drug level gemcitabine affect use LDE-225 . Two additional biopsy require participate study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>.Histologically cytologically confirm adenocarcinoma pancreas . Must borderline resectable pancreatic adenocarcinoma Measurable disease , define least one lesion accurately measure least one dimension No previous radiotherapy , surgery , chemotherapy investigational drug therapy . Age &gt; 18 year .Life expectancy great 1 month . ECOG performance status 0 1 Adequate organ marrow function .Asymptomatic jaundice ascites . Pain symptoms stable . Negative serum pregnancy test Sexually active male agree use barrier form contraception , even vasectomy , study 6 month stop LDE225 . Males donate sperm treatment , six month last dose . Sexually active female child bear potential agree use highly effective contraception study 20 month final dose LDE225 . .Agree donate blood product 12 month stop LDE225 . .Willing two biopsy treatment correlative study . History allergic reaction attribute compound similar chemical biologic composition LDE225 agent use study . Patients take medication narrow therapeutic index metabolize cytochrome P450 ( CYP450 ) , include warfarin sodium ( CoumadinÂ® ) Uncontrolled illness include , limited , ongoing active infection require IV antibiotic , symptomatic congestive heart failure control medication , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude Patient undergone major surgery , diagnostic surgery within four week prior start treatment study . Patients receive treatment medication know moderate strong inhibitor inducer CYP3A4/5 drug metabolize CYP2B6 CYP2C9 narrow therapeutic index , discontinue start treatment LDE225 . Medications strong CYP3A4/5 inhibitor discontinue least 7 day strong CYP3A/5 inducer least 2 week prior start treatment LDE225 . .Patients neuromuscular disorder . .Patients impaired cardiac function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pancreatic ductal adenocarcinoma ( PDA ) Neoplasms</keyword>
	<keyword>LDE225</keyword>
	<keyword>nab-paclitaxel</keyword>
	<keyword>abraxane</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>cytotoxic</keyword>
	<keyword>hedgehog ( Hh ) inhibitor</keyword>
	<keyword>stromal cell</keyword>
	<keyword>resectable PDA</keyword>
	<keyword>Pancreatic Diseases</keyword>
	<keyword>Carcinoma</keyword>
</DOC>